Overview Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Status: Recruiting Trial end date: 2026-07-31 Target enrollment: Participant gender: Summary This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors. Phase: Phase 1 Details Lead Sponsor: Revolution Medicines, Inc.